Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00033943 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of OP2000 (Deligoparin) in the Treatment of Active Ulcerative Colitis
A Phase 2 study of Ulcerative Colitis, sponsored by Incara Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 270
- Enrollment target
- 20
- Study locations
NCT00033943: Completed Phase 2 study of Ulcerative Colitis, sponsored by Incara Pharmaceuticals.
NCT00033943 is a Phase 2 study of Ulcerative Colitis that has completed, run by Incara Pharmaceuticals. The registered enrollment target is 270 participants, below the 2,055-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (87% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00033943, a Phase 2 study of Ulcerative Colitis, has completed, sponsored by Incara Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 270 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will evaluate the effectiveness and safety of the experimental compound OP2000 (deligoparin) in patients with active ulcerative colitis. Patients eligible for this study will have received (and will continue to receive) stable doses of aminosalicylates (oral, enema and/or suppository), if tolerated. OP2000 is an ultra low molecular weight heparin with anticoagulant (blood thinning) and anti-inflammatory actions that may be of benefit for the treatment of ulcerative colitis.
Conditions Studied
Interventions
- DRUG deligoparin
Study Locations (20)
Florida
- University of Florida Gainesville/Gainesville VAMC - Gainesville
- Borland-Groover Clinic - Jacksonville
- University of Miami, Division of Clinical Pharmacology - Miami
- Miami Research Associates - Miami
North Carolina
- Univ. of North Carolina Hospital - Chapel Hill
- Charlotte Gastroenterology & Hepatology, PLLC - Charlotte
- Duke Health Center - Durham
California
- AGMG Clinical Research - Anaheim
- Community Clinical Trials - Orange
Colorado
- Rocky Mountain Gastroenterology Associates - Lakewood
- Rocky Mountain Clinical Research - Littleton
New York
- Long Island Clinical Research Associates - Great Neck
- Daniel H. Present, MD - New York
Georgia
- Atlanta Gastroenterology Associates, LLC - Atlanta
Kentucky
- Univ. of Kentucky Medical Center - Lexington
Maryland
- Metropolitan Gastroenterology Group - Chevy Chase
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 270 participants |
| Start Date | 2001-01 |
| Est. Completion | 2002-09 |
| Phase | Phase 2 |
What the finished NCT00033943 record still lists
NCT00033943 is an interventional study that assigns participants to a tested intervention. The registered 270 participants enrollment target is mid-sized for trials with a published cap, below the 2,055-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (87% lower).
The record links to 1 condition, with Ulcerative Colitis appearing as the primary indexed condition, and to 1 intervention - of which deligoparin is the first listed.
NCT00033943 names 20 study sites across 12 states, led by Florida, North Carolina, California.
Frequently Asked Questions
What is clinical trial NCT00033943 about?
NCT00033943 is a clinical study titled "Safety and Efficacy of OP2000 (Deligoparin) in the Treatment of Active Ulcerative Colitis". This study will evaluate the effectiveness and safety of the experimental compound OP2000 (deligoparin) in patients with active ulcerative colitis. Patients eligible for this study will have received (and will continue to receive) stable doses of aminosalicylates (oral, enema and/or suppository), if...
What is the current status of trial NCT00033943?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 270 participants. The study started on 2001-01. Estimated completion is 2002-09.
What conditions does trial NCT00033943 study?
This clinical trial studies the following conditions: Ulcerative Colitis.
What interventions are being tested in trial NCT00033943?
The interventions under investigation include: deligoparin (DRUG).
Who is sponsoring clinical trial NCT00033943?
This trial is sponsored by Incara Pharmaceuticals, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00033943 being conducted?
This trial has 20 study locations across California, Colorado, Florida, Georgia, Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ulcerative Colitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00033943's enrollment target sits among peer trials
270 36th of 122 higher than 87 of 122 other Ulcerative Colitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ulcerative Colitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)
RECRUITING · Phase 2
-
Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis
RECRUITING · Phase 2
-
A Study of Eltrekibart and Mirikizumab in Adult Patients With Moderately to Severely Active Ulcerative Colitis
RECRUITING · Phase 2
-
Treatment of UC With Novel Therapeutics
RECRUITING · Phase 2
-
A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis
RECRUITING · Phase 2
-
A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00801489 · 270 participants · Phase 2
Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
- NCT04372485 · 270 participants · NA
Using Mobile Health (mHealth) to Improve STI Treatment Adherence Among Adolescents
- NCT04528446 · 270 participants
The Impact of Glomerular Disorders on Bone Quality and Strength
- NCT05215327 · 270 participants · Phase 2
High vs. Standard Dose Influenza Vaccine in Lung Allograft Recipients
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia